Equilibre Biopharmaceuticals

Closed

New York, United States · Founded 2020 · $31.0M raised

Headquarters
New York, New York
Employees
1–10
Founded
2020
Business Model
B2B
Total Funding
$31.0M
Last Round
$6.0M Venture RoundDec 2022
Rounds
2

About

Equilibre Biopharmaceuticals Corp. (also known as Equilibre Neuroscience) was a New York City-based specialty pharmaceutical company founded in 2020 by biotech entrepreneur Sam Waksal, focused on neuroscience and rare-disease drug development. The company licensed assets including a ROCK2 inhibitor program later spun out as Graviton Bioscience. Equilibre appears to have ceased normal operations amid financial distress — its website went offline between August 2023 and January 2024 — and is now the subject of a bankruptcy trustee's lawsuit against its former CEO, reported by STAT News in April 2025.

Summary

Equilibre Biopharmaceuticals is a Biotech company based in New York, United States, founded in 2020. It has raised $31.0M in total across 2 rounds, most recently a $6.0M Venture Round round in Dec 2022. Investors include Third Point Ventures.

Funding History

Venture RoundVenture RoundDec 2022
$6.0M

Sign up to see all 2 rounds

Venture Round — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Equilibre Biopharmaceuticals on Indexed.vc
<a href="https://indexed.vc/companies/equilibre-biopharmaceuticals"><img src="https://indexed.vc/api/badge/company/equilibre-biopharmaceuticals" alt="Equilibre Biopharmaceuticals on Indexed.vc" width="260" height="76" /></a>